Cover Image
市場調查報告書

心血管設備:新興市場上的成長機會

Cardiovascular Devices - Growth Opportunities in Emerging Markets

出版商 Life Science Intelligence, Inc. 商品編碼 302710
出版日期 內容資訊 英文 68 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
心血管設備:新興市場上的成長機會 Cardiovascular Devices - Growth Opportunities in Emerging Markets
出版日期: 2014年05月20日 內容資訊: 英文 68 Pages
簡介

2013年在金磚四國(巴西,俄羅斯,印度,中國)及土耳其的新興5個國家,推算實施的心血管手術上升到220萬件,今後預測約以13%的CAGR成長,2017年增加到350萬件以上。單就中國2013年的該手術數構成約60%(130萬件),預計今後5年的成長率最高達16.8%。

本報告提供新興5個國家(巴西、俄羅斯、印度、中國及土耳其)的心血管設備市場相關調查、市場概要、各手術類型(冠狀動脈血管重建手術、心律管理手術、心臟瓣膜手術)分析、各國的市場機會、技術趨勢,及今後展望等彙整資料。

市場概要

  • 促進成長要素、阻礙要素
  • 人口、疾病趨勢
  • 糖尿病的流行
  • 缺血性心臟疾病(IHD)的得病率的上升
  • 主要的心血管設備的機會

冠狀動脈血管重建手術

  • PCI:新興市場提供最好的成長機會
  • 藥劑溶出性血管支架(DES)的強烈需求
  • 輻射狀PCI的增加
  • CABG手術

心律管理手術

  • CRT顯示確實的利益構造
  • 心導管電氣燒灼術:達到臨界點

心臟瓣膜手術

新興市場上心血管設備的機會:各國

中國

  • 中國的醫療市場:機會與課題
  • 中國的心臟病市場成長機會:前五名
  • 中國的PCI手術
  • 中國的CRM手術
  • 中國的心臟瓣膜手術
  • 其他中國的高成長/數量多的手術
  • 多國籍心血管設備企業將中國視為新興市場策略的「關鍵」

印度

  • 印度的心臟病市場成長機會:前五名
  • 心律管理手術:印度成長的領導者
  • 印度的PCI手術
  • 印度的CABG、心臟瓣膜手術
  • 印度的先天性心臟病(CHD)手術

巴西

  • 巴西的心臟病市場成長機會:前五名
  • 巴西的心臟瓣膜手術
  • 巴西的主動脈瘤修復、其他

俄羅斯

  • 俄羅斯的心臟病市場成長機會:前五名
  • 俄羅斯的介入心血管手術
  • 俄羅斯的心律手術
  • 俄羅斯的及其他的手術

土耳其

  • 土耳其的心臟病市場主要成長機會
  • 土耳其的PCI手術
  • 土耳其對跨國公司來說富有魅力

跨國公司關注成長的新興市場

  • Medtronic:新興市場策略的案例研究

新興市場上新技術的影響

  • Boston Scientific
  • St. Jude Medical
  • Abbott Vascular

圖表清單

目錄

A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey. Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%).

Interventional cardiology procedures, heart rhythm procedures, and heart valve procedures (particularly minimally invasive valve procedures) are expected to exhibit the highest procedural growth over the next several years in these five nations, with solid double-digit growth rates anticipated for all of these procedure categories through 2017. These same categories also represent four of the top five cardiovascular markets by procedure volume, with percutaneous coronary intervention, accounting for more than 60% of that total.

Demand for cardiovascular devices in the BRIC nations and Turkey is expected to remain high over the next five years, driven by aging populations, expanding rates of diabetes and heart disease, an ongoing trend toward urbanization, and continued government investments in healthcare infrastructure. At the same time, these countries present some important challenges to foreign companies seeking to do business there, including weak patent laws, the potential for corruption, and disparities in access to healthcare.

This dynamic, new report from Life Science Intelligence offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions.

COMPANIES COVERED

  • 1.Abbott Laboratories
  • 2.Abbott Vascular
  • 3.Apollo Hospitals Enterprise Ltd.
  • 4.Biosense Webster/Johnson & Johnson
  • 5.Biostar
  • 6.Boston Scientific
  • 7.China Kanghui Holdings
  • 8.Covidien
  • 9.Edwards Lifesciences
  • 10.GE Healthcare
  • 11.LifeTech Scientific Corp.
  • 12.Medicall Biomedikal AS
  • 13.Medtronic
  • 14.Philips Medical
  • 15.St. Jude Medical
  • 16.Stryker
  • 17.Terumo

Table of Contents

MARKET OVERVIEW

  • Growth Drivers and Limiters
  • Population and Disease Trends
  • The Diabetes Pandemic
  • Rising Prevalence of Ischemic Heart Disease
  • Top Cardiovascular Device Opportunities

CORONARY REVASCULARIZATION

  • PCI: Emerging Markets offer A Rare Growth Opportunity
  • Strong Demand For Drug-Eluting Stents
  • Radial PCI On The Rise
  • CABG Surgery

CARDIAC RHYTHM MANAGEMENT PROCEDURES

  • CRT Poised For Solid Gains
  • Cardiac Ablation: Reaching Critical Mass

HEART VALVE PROCEDURES

CARDIOVASCULAR DEVICE OPPORTUNITIES IN EMERGING MARKETS, BY COUNTRY

CHINA

  • China's Healthcare Market: Opportunities and Challenges
  • Top Five Cardiovascular Growth Opportunities in China
  • PCI Procedures in China
  • CRM Procedures in China
  • Heart Valve Procedures in China
  • Other High-Growth/High-Volume Procedures in China
  • Multinational Cardiovascular Device Players See China As "Key" To Emerging Market Strategy

INDIA

  • Top Five Cardiovascular Growth Opportunities in India
  • Cardiac Rhythm Management Procedures: Growth Leader in India
  • PCI Procedures in India
  • CABG and Heart Valve Procedures in India
  • Congenital Heart Disease Procedures in India

BRAZIL

  • Top Five Cardiovascular Growth Opportunities in Brazil
  • Heart Valve Procedures in Brazil: Growth in MIS
  • Aortic Aneurysm Repair in Brazil
  • Brazil's Loss Leaders

RUSSIA

  • Top Five Cardiovascular Growth Opportunities in Russia
  • interventional Cardiology Procedures in Russia
  • Heart Rhythm Procedures in Russia
  • Other Growth Procedures in Russia

TURKEY

  • Top Growth Procedures in Turkey
  • PCI Procedures in Turkey
  • Turkey Attracts Multinationals

MULTINATIONALS LOOK TO EMERGING MARKETS FOR GROWTH

  • Medtronic: A Case Study in Emerging Market Strategy

IMPACT OF NEW TECHNOLOGIES IN EMERGING MARKETS

  • Boston Scientific
  • St. Jude Medical
  • Abbott Vascular

LIST OF EXHIBITS

  • Exhibit 1: Global Cardiovascular Therapeutic Device Market, 2014
  • Exhibit 2: Cardiovascular Procedures in the BRIC Nations and Turkey
  • Exhibit 3: Cardiovascular Procedure Growth, BRIC Nations and Turkey
  • Exhibit 4: Population Rankings for the BRIC Nations and Turkey, 2014
  • Exhibit 5: Growth in Per Capita Government Expenditures on Health
  • Exhibit 6: Growth in Age 65 and Over Populations, Emerging Countries, 2012-2017E
  • Exhibit 7: Top 10 Countries/Territories For Number of People with Diabetes (Age 20-79 years), 2013 and 2035
  • Exhibit 8: Population with Ischemic Heart Disease (000s), 2012-2017E
  • Exhibit 9: Population with Ischemic Heart Disease (000s), 2017, by Country
  • Exhibit 10: Emerging Markets: Top 10 Procedure Volume Growth Opportunities for Cardiovascular Devices, 2012-2017E
  • Exhibit 11: Emerging Markets: Top Five Cardiovascular Markets by Case Volume, 2014E
  • Exhibit 12: Emerging Market Contribution to Worldwide PCI Device Revenues, 2013-2017E
  • Exhibit 13: Percutaneous Coronary intervention, Emerging Markets Procedure Forecast Versus US and Germany, 2012-2017E
  • Exhibit 14: Stent Implantations (units), Emerging Markets Forecast, 2012-2017E
  • Exhibit 15: DES Implantations (units), Emerging Markets Forecast, 2012-2017E
  • Exhibit 16: Growth in Radial Access For PCI: Emerging Nations vs. US and Germany
  • Exhibit 17: CABG Surgery, Emerging Markets Procedure Forecast Versus US and Germany, 2012-2017E
  • Exhibit 18: Global CRM Device Market; Share by Supplier, 2014
  • Exhibit 19: CRM Procedures, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 20: CRT/CRT-D Implantations, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 21: CRT-P and CRT-D Procedural Growth Projections in the BRIC Nations and Turkey, 2012-2017
  • Exhibit 22: Conventional Pacemaker Implantations, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 23: ICD Implantations, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 24: Global AF Device Market; Share by Supplier, 2014
  • Exhibit 25: Worldwide Electrophysiology Device Market, Revenue Forecast, 2012-2017E
  • Exhibit 26: Cardiac Ablation, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 27: TAVR Global Market Forecast, 2013-2019E
  • Exhibit 28: Heart Valve Procedures,Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 29: Minimally invasive Valve Procedures, Emerging Markets Procedure Forecast, 2012-2017E
  • Exhibit 30: Growth in China's Middle Class; Percent of Urban Chinese Households With Middle Class incomes, 2000-2022
  • Exhibit 31: Ischemic Heart Disease in China, 2012-2017E
  • Exhibit 32: Leading Causes of Death in China
  • Exhibit 33: China: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
  • Exhibit 34: China: Top Five Cardiovascular Procedures by Volume, 2014
  • Exhibit 35: Percutaneous Coronary intervention in China, 2012-2017E
  • Exhibit 36: CRM Procedures in China, 2012-2017E
  • Exhibit 37: CRM Procedures in China, by Product Type, 2014
  • Exhibit 38: Heart Valve Procedures in China, 2012-2017E
  • Exhibit 39: Congenital Heart Disease Procedures in China, 2012-2017E
  • Exhibit 40: CABG Surgery, Cardiac Ablation, and Aortic Aneurysm Procedure Volumes in China, 2012-2017E
  • Exhibit 41: India: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
  • Exhibit 42: India: Top Five Cardiovascular Procedures by Case Volume, 2014
  • Exhibit 43: Ischemic Heart Disease Prevalence in India, 2012-2017E
  • Exhibit 44: CRM Procedures in India, 2012-2017E
  • Exhibit 45: Cardiac Ablation in India, Procedure Forecast, 2012-2017E
  • Exhibit 46: Percutaneous Coronary intervention in India, 2012-2017E
  • Exhibit 47: CABG and Heart Valve Procedures in India, 2012-2017E
  • Exhibit 48: Congenital Heart Disease Procedures in India, 2012-2017E
  • Exhibit 49: Brazil: Top Five Cardiovascular Procedures by Case Volume, 2014
  • Exhibit 50: Brazil: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
  • Exhibit 51: Top Ten Causes of Death in Brazil, 2010
  • Exhibit 52: Trends in Coronary Stenting in Brazil
  • Exhibit 53: CRM Procedures in Brazil, 2012-2017E
  • Exhibit 54: Heart Valve Procedures in Brazil, 2012-2017
  • Exhibit 55: Aortic Aneurysm Repair Procedures in Brazil, 2012-2017E
  • Exhibit 56: Physicians Per 1,000 Population; BRIC Nations vs. Selected Others
  • Exhibit 57: Russia: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
  • Exhibit 58: Russia: Top Five Cardiovascular Procedures by Case Volume, 2014
  • Exhibit 59: Trends in Coronary intervention in Russia, 2012-2017E
  • Exhibit 60: Pacemaker Implants and CABG Surgery in Russia, 2012-2017E
  • Exhibit 61: Trends in Heart Valve Procedures in Russia, 2012-2017E
  • Exhibit 62: Aortic Aneurysm Repair Procedures in Russia, 2012-2017E
  • Exhibit 63: Turkey: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
  • Exhibit 64: Turkey: Top Five Cardiovascular Procedures by Case Volume, 2014
  • Exhibit 65: Percutaneous Coronary intervention in Turkey, 2012-2017E
  • Exhibit 66: Moderate Volume/Growth Opportunities in Turkey
  • Exhibit 67: Medtronic's Emerging Market Revenue Mix, FY2013
Back to Top